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Introduction
Uveal melanoma is the most common
primary intraocular tumour in adults.
Up to 50% of patients may develop
systemic metastasis with a fatal out-
come (Kujala et al. 2003). Enucleation
had been the standard treatment, but
eye-conserving plaque radiotherapy
has become a popular alternative.
Brachytherapy using isotopes such as
Ruthenium (Ru)-106 and Iodine (I)-
125 has achieved local control rates
above 90% at 5 years (Char et al.
2002; Damato et al. 2005) and sur-
vival rates comparable to those of
enucleation (COMS report No. 28.
2006). Despite current developments
in diagnosis and treatment, the sur-
vival rate of uveal melanoma has not
signiﬁcantly changed for the last sev-
eral decades because of limited knowl-
edge of its molecular biology and lack
of active treatments for metastatic dis-
eases. Although speciﬁc cytogenetic
abnormalities, especially monosomy 3,
have been closely associated with met-
astatic disease and shed some light on
this subject, the mechanisms of uveal
melanoma progression and metastasis
remain poorly understood (Prescher
et al. 1996; Damato et al. 2007; Lee
et al. 2011).
Angiogenesis plays a critical role in
the development and progression of
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ABSTRACT.
Purpose: To determine the aqueous humour levels of 12 cytokines in eyes with
uveal melanoma and whether their expression changes after combined Ru-106
brachytherapy and transpupillary thermotherapy (TTT).
Methods: Aqueous humour samples were collected from 20 patients with previ-
ously untreated uveal melanoma undergoing combined Ru-106 brachytherapy
and TTT, both at the time of plaque placement and removal. Using multiplex
biochip array technology, 12 different cytokines were measured, including
interleukin (IL)-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, vascular endothelial
growth factor (VEGF), tumour necrosis factor (TNF)-a, interferon (IFN)-c,
epidermal growth factor (EGF) and monocyte chemoattractant protein
(MCP)-1. Aqueous humour from 20 patients undergoing cataract surgery was
used as control.
Results: IL-6, IL-8, IFN-c and MCP-1 were highly expressed in uveal mela-
noma, whereas IL-2, IL-10 and TNF- a were low in expression. There was a
positive correlation between tumour height and IL-8 level (p = 0.020). Vascu-
lar endothelial growth factor tends to be highly expressed in melanoma-con-
taining eyes (p = 0.056). Levels of IL-6, IL-8 and IL-1b increased after the
mean 117 ± 38 hrs of brachytherapy and adjunctive TTT with a tumour apex
dose of 61 ± 28 Gy and a scleral contact dose of 786 ± 226 Gy. Increase in
levels of IL-6 (p = 0.003) and IL-8 (p = 0.046) positively correlated with
scleral contact dose.
Conclusions: Cytokines such as IL-6, IL-8, IFN-c and MCP-1 may be impli-
cated in the progression of uveal melanoma. Ocular irradiation from a Ru-106
plaque promoted an increase in the levels of IL-6, IL-8 and IL-1b, modulation
of which could be useful in managing radiation-related side effects.
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all malignant tumours (Hanahan &
Weinberg 2000). As the eye has no
lymphatic drainage, the metastasis of
uveal melanoma is primarily hemato-
genous; therefore, angiogenesis may
be even more important in the biology
of this tumour. Inﬂammation,
together with angiogenesis, contrib-
utes to an important aspect of cancer
immunity. Studying the expression of
angiogenic and inﬂammatory factors
in uveal melanoma can provide valu-
able information about tumour biol-
ogy and is important for development
of new treatments.
During brachytherapy for uveal
melanoma, radioactive plaques that
are sutured to sclera overlying the
tumour emit b- (Ru-106) or c-irradia-
tion (I-125) that kills cancerous cells.
As an adjunctive treatment to brachy-
therapy, especially in large tumours,
transpupillary thermotherapy (TTT)
using an infrared laser can be used
(Oosterhuis et al. 1995; Shields et al.
2002; Bartlema et al. 2003). Despite
the eye-conserving advantage over
enucleation, various vision-affecting
side effects from radiation have been
described after brachytherapy, includ-
ing cataract, radiation retinopathy,
optic neuropathy, neovascular glau-
coma, retinal detachment, keratitis,
vitreous haemorrhage and uveitis
(Shields et al. 2002; Puusaari et al.
2004). Study of changes in intraocular
environment following brachytherapy
can be useful for understanding of its
therapeutic effects and prevention or
management of radiation-related com-
plications.
Using a multiplex biochip array
system, we determined the baseline
and posttreatment expression of
12 immune cytokines in aqueous
humours from melanoma-containing
eyes that received brachytherapy using
Ru-106 plaque and adjunctive TTT as
a primary therapy.
Methods and Materials
This study followed the tenets of the
Declaration of Helsinki and was
approved by the Institutional Review
Board of Yonsei University Medical
Center, Seoul, Korea. All patients
signed a written informed consent
after an explanation of the nature and
possible consequences of this study.
Patients diagnosed with uveal mela-
noma at the Ophthalmology Depart-
ment of Yonsei University Medical
Center between 1 January 2009 and
31 December 2010 were included in
the study. Exclusion criteria included
(i) a history of any treatment for
uveal melanoma, (ii) a history of any
intraocular surgery in the affected eye,
(iii) concomitant ocular disorders in
the affected eye that could confound
interpretation of cytokine levels, such
as diabetic retinopathy, and (iv) pri-
mary treatment other than combined
brachytherapy using a Ru-106 plaque
(BEBIG, Berlin, Germany) and TTT.
Diagnosis of uveal melanoma was
established by a comprehensive oph-
thalmic examination, ultrasonography,
ﬂuorescein angiography and magnetic
resonance imaging. Largest basal
diameter (LBD) and tumour thickness
were measured with B-scan ultraso-
nography (Hi-Scan; Optikon 2000,
Rome, Italy).
Undiluted aqueous humour samples
(100 ll) were obtained through ante-
rior chamber paracentesis using a 30
gauge needle from 20 eyes of uveal
melanoma patients just before they
underwent TTT and Ru-106 brachy-
therapy in the operating room. After
removal, aqueous humour was not
replaced by any material. All cases
with brachytherapy received adjunc-
tive TTT of the tumour apex using an
indirect ophthalmoscope in the oper-
ating room before placing the Ru-106
plaque. Exposure time was 1 min per
application, and laser energy was
adjusted stepwise until the tumour
surface turned slightly gray at the end
of a 1-min exposure. In ﬁve eyes, rec-
tus muscles (two inferior, two lateral
and one medial) were removed at the
time of plaque implantation and repo-
sitioned at the original insertion site
when the plaque was removed. In one
eye, an inferior oblique muscle was
detached and left disinserted. Undi-
luted aqueous humour samples
(100 ll) were re-collected just before
the plaque was removed under local
anaesthesia.
Undiluted aqueous humours
(100 ll) were also obtained as control
samples from 20 patients without ocu-
lar pathology other than cataracts,
immediately before their cataract sur-
gery using a 30 gauge needle and
replaced with viscoelastic materials.
Aqueous humour samples were trans-
ferred to sterile tubes and stored at
)76C until the assay. The aqueous
levels of 12 cytokines were simulta-
neously determined using a commer-
cially available multiplex biochip
array system (EVIDENCE Investiga-
tor Biochip Array Technology;
Randox Laboratories Ltd., Crumlin,
UK) (Molloy et al. 2005). Analyzed
cytokines included interleukin (IL)-1a,
IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10,
vascular endothelial growth factor
(VEGF), tumour necrosis factor
(TNF)-a, interferon (IFN)-c, epider-
mal growth factor (EGF) and mono-
cyte chemoattractant protein (MCP)-
1. Samples were immediately thawed
before analysis, and undiluted samples
were directly applied to each reaction
well in the biochip, a solid substrate
with multiple speciﬁc cytokine anti-
bodies attached at predeﬁned sites on
the surface. After each cytokine was
bound to its speciﬁc antibody, appro-
priate enzyme-labelled secondary anti-
bodies were added and cytokine levels
were quantiﬁed by chemiluminescence
using a charge-coupled device camera
and imaging system. The analyte con-
centration was calculated from the
calibration curve. If the concentra-
tions of the raw data were less than
the minimal detectable levels or more
than the maximal levels, they were set
to zero or the maximal level of each
calibration curve.
The Mann–Whitney U test and
Pearson’s chi-squared test were per-
formed to compare the differences in
demographics and expression of cyto-
kines between the uveal melanoma
group and control group. The Wilco-
xon signed rank test was performed to
compare the cytokine levels before
brachytherapy with adjunctive TTT
and after plaque removal. Spearman’s
rho was performed to assess whether
there were correlations between cyto-
kine levels. Linear regression was
applied to see whether clinical charac-
teristics correlated with each cytokine
levels before treatment and to deter-
mine which factors affected the differ-
ences in cytokine levels following the
treatment. All data were analyzed
using spss 15.0 for Windows (SPSS,
Inc., Chicago, IL, USA). A p value
<0.05 was considered statistically sig-
niﬁcant.
Results
During the study period, 34 patients
were diagnosed with uveal melanoma
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in our institute. Of these patients, four
had received previous surgeries or
radiation therapy for uveal melanoma,
and one had concurrent diabetic reti-
nopathy. Nine patients underwent pri-
mary enucleation. All of these 14
patients were excluded from the study.
Remaining 20 patients underwent
combined Ru-106 Brachytherapy and
TTT. Subsequently, aqueous humour
samples were obtained from 20 uveal
melanoma patients before and after
plaque irradiation. The mean and
standard deviation of tumour apex
dose and scleral contact dose was
61 ± 28 and 786 ± 226 Gy, respec-
tively. Plaque removal occurred at a
mean of 117 ± 38 hrs.
Demographics of patients are pro-
vided in Table 1. The mean age of
patients was 48 years (range, 25–69),
and 14 (70%) were men. There was a
signiﬁcant difference in age between
the uveal melanoma group and the
control group (48 and 58, respec-
tively). However, a linear regression
test showed that there was no correla-
tion between age and expression of
each cytokine level (data not shown).
The mean visual acuity was 20 ⁄ 80
(range, HM-20 ⁄ 20). The mean LBD
of the tumour was 12.3 mm (range,
7.6–17.3), and the mean height was
6.6 mm (range, 3.7–9.8). No tumour
involved ciliary body. Serous retinal
detachment involving more than 1
quadrant of retina was present in nine
eyes (45%).
Aqueous humour levels of 12 cytokines
No case showed complication after
anterior chamber paracentesis. The
cytokine levels in the aqueous humour
samples are provided in Table 2. The
following cytokines were not detected
in the aqueous humour of melanoma-
containing eyes and were set to zero:
IL-2 in 9 (45%) patients; IL-4 in 1
(5%) patient, IL-10 in 9 (45%)
patients; TNF-a in 13 (65%) patients;
IL-1a in 5 (25%) patients; IL-1b in 8
(40%) patients; and EGF in 6 (30%)
patients. The aqueous humour level of
MCP-1 in uveal melanoma was set to
900 in 14 (70%) patients, because this
was the maximal level of the standard
curve (900 pg ⁄ml). In the control
group, following cytokines were not
detectable and were set to zero: IL-2
in 1 (5%), IL-10 in 3 (15%), INF-c in
4 (20%), TNF-a in 7 (35%), IL-1a in
2 (10%), IL-1b in 3 (15%) and EGF
in 5 (25%).
The levels of IL-2, IL-10 and TNF-
a signiﬁcantly decreased, whereas IL-
6, IL-8, IFN-c and MCP-1 were
increased in the uveal melanoma
group, compared with the control
group. The VEGF level tended to be
higher in the uveal melanoma group,
but this increase was not statistically
signiﬁcant (p = 0.056).
Some cytokines correlated with each
other in their expression (Table 3).
Positive correlation was seen between
VEGF and IL-6 (p = 0.034), VEGF
and IL-8 (p = 0.030), IL-4 and IFN-c
(p < 0.001), IL-4 and IL-1a
(p = 0.019), and IL-2 and EGF
(p = 0.035).
Comparison study between clinical
characteristics (age, LBD, humour
height, anterior and posterior tumour
margin, and degree of associated reti-
nal detachment) and cytokine concen-
trations showed a positive correlation
between tumour height and IL-8
(p = 0.020) and degree of retinal
detachment and VEGF (p = 0.018).
Short-term changes in aqueous humour
cytokine levels of after brachytherapy
We aimed to assess the short-term
effect of Ru-106 brachytherapy and
adjunctive TTT on the tumour envi-
ronment by comparing cytokine levels
before and after brachytherapy. Levels
of IL-6, IL-8 and IL-1b signiﬁcantly
increased during therapy (Table 2).
Positive correlations were seen
between scleral contact dose and
increase in levels of IL-6 (Fig. 1) and
IL-8 (Fig. 2), which were calculated
by subtraction of the baseline value
from the ﬁnal value. Comparison
study between clinical characteristics
and increase in levels of IL-6, IL-8
and IL-1 b showed a positive correla-
tion between tumour height and
increase in IL-6 (p = 0.041) and IL-8
(p = 0.033).
Discussion
We used the multiplex biochip array
system to simultaneously analyze
the aqueous levels of 12 different
cytokines in patients with uveal
melanoma. The aqueous levels of
seven cytokines signiﬁcantly differed
between the melanoma-containing
eyes and control eyes; IL-2, IL-10 and
TNF-a were low, while IL-6, MCP-1,
Table 1. Demographics of choroidal melanoma group and control group.
Feature Melanoma group Control group p-value
No. of eyes 20 20
Male ⁄ female (no. of patients) 14 ⁄ 6 9 ⁄ 11 0.110
Right ⁄ left (no. of eyes) 8 ⁄ 12 9 ⁄ 11 0.749
Mean age in years (±SD) 48 (±14) 58 (±10) 0.024
Associated systemic ﬁndings 0.343
None 13 (65%) 15 (75%)
Hypertension 5 (25%) 5 (25%)
Gastrointestinal stromal tumour 1 (5%) 0 (0%)
Ovarian benign tumour 1 (5%) 0 (0%)
Mean snellen visual acuity (range) 20 ⁄ 80 (HM-20 ⁄ 20) 20 ⁄ 50 (20 ⁄ 400–20 ⁄ 32) 0.758
Mean tumour size in mm (±SD)
Largest basal diameter 12.3 (±2.7) –
Height 6.9 (±1.9) –
Anterior margin of tumour (no. of eyes)
Pre-ora serrata 0 (0%) –
Post-ora serrata 20 (100%) –
Posterior margin of tumour (no. of eyes)
1–2 DD from fovea 2 (10%) –
<1 DD from fovea 5 (25%) –
1–2 DD from optic disk 3 (15%) –
<1 DD from optic disk 2 (10%) –
>2 DD from fovea or optic disk 8 (40%) –
Associated serous retinal detachment (no. of eyes)
<1quadrant 11 (55%) –
1–2 quadrants 7 (35%) –
>2 quadrants 2 (10%) –
DD = disk diameter; HM = detecting hand movement; SD = standard deviation.
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IL-8 and IFN-c were high in mela-
noma-containing eyes.
Uveal melanoma progression has
been attributed to a variety of
immune evasion strategies, including
down-regulation of IL-2 (Yang et al.
2008). IL-2 acts as a growth factor
and activator of T cells, resulting in
increased number of cytotoxic T cells
that can kill tumour cells. Investiga-
tors have used systemic IL-2 in the
treatment of various tumours with
varying success, including metastatic
cutaneous melanoma, but did not
show promising results for uveal mela-
noma (Atkins et al. 1999).
IL-10 is a Th2-speciﬁc cytokine and
generally acts as an anti-inﬂammatory
cytokine. IL-10 was shown to be
expressed in several uveal melanoma
cell lines, which may be important for
evading the immune surveillance
(Ijland et al. 1999). In case of an
intraocular lymphoma, elevated ratios
of vitreous IL-10 to IL-6 were sug-
gested to be diagnostic (Whitcup et al.
1997). In our cases, aqueous IL-10
was not increased in melanoma-con-
taining eyes and expression of IL-6
was signiﬁcantly higher than that of
IL-10. A recent study also showed
that on average, IL-6 was higher than
IL-10 in uveal melanoma(Ly et al.
2010).
TNF-a is a proinﬂammatory cyto-
kine that can inhibit tumorigenesis.
Regional application of high-dose
TNF-a has shown some successes with
cutaneous melanoma (Lejeune et al.
1998). However, its role in melanoma
appears to be complicated; it has been
shown that TNF-a can actually up-
regulate melanoma invasion and
migration in vitro (Katerinaki et al.
2003).
IL-6 is a pro-inﬂammatory cytokine
typically produced by T lymphocytes
and macrophages. Various malignant
tumour cells have also been reported
to produce IL-6 including cutaneous
and uveal melanomas (Colombo et al.
1992; Cools-Lartigue et al. 2004). IL-6
can stimulate tumour cell growth as
an autocrine growth factor or through
the inhibition of apoptosis (Kawano
et al. 1988). Another possible source
of IL-6 is tumour-associated macro-
phages (TAMs) in uveal melanoma
(Elgert et al. 1998). In fact, IL-6 was
suggested as an important cytokine in
Table 2. Aqueous humour cytokine levels in the control group and uveal melanoma group before and after Ru-106 brachytherapy and transpup-





after treatment p-value* p-value
EGF(pg ⁄ml) 0.9 ± 0.8 1.0 ± 0.8 1.0 ± 0.9 0.820 0.698
IFN-c(pg ⁄ml) 2.2 ± 2.2 6.9 ± 6.7 6.2 ± 5.2 0.001 0.681
IL-1a(pg ⁄ml) 0.5 ± 0.3 0.5 ± 0.3 0.4 ± 0.3 0.565 0.856
IL-1b(pg ⁄ml) 0.6 ± 0.3 0.5 ± 0.5 1.0 ± 0.8 0.314 0.008
IL-2(pg ⁄ml) 4.1 ± 2.2 2.3 ± 2.5 1.8 ± 2.2 0.018 0.300
IL-4(pg ⁄ml) 4.3 ± 2.1 3.3 ± 1.7 3.9 ± 2.0 0.183 0.103
IL-6(pg ⁄ml) 5.7 ± 6.1 108.4 ± 168.4 321.3 ± 280.9 <0.001 <0.001
IL-8(pg ⁄ml) 8.5 ± 8.0 25.1 ± 18.4 57.9 ± 54.7 <0.001 0.001
IL-10(pg ⁄ml) 0.7 ± 0.6 0.4 ± 0.4 0.5 ± 0.4 0.026 0.115
MCP-1(pg ⁄ml) 434.0 ± 198.0 862.6 ± 63.8 864.8 ± 84.8 <0.001 0.575
TNF-a(pg ⁄ml) 1.5 ± 2.3 0.3 ± 0.5 0.5 ± 0.6 0.005 0.139
VEGF(pg ⁄ml) 45.6 ± 35.7 109.5 ± 117.6 175.1 ± 198.1 0.056 0.100
EGF = epidermal growth factor; IFN = interferon; IL = interleukin; MCP = monocyte chemoattractant protein; TNF = tumour necrosis fac-
tor; VEGF = vascular endothelial growth factor.
* Mann–Whitney U test between control and melanoma group before therapy.
 Wilcoxon signed rank test between before and after treatment for melanoma.
Table 3. p-values* of correlation between aqueous humour cytokine levels in uveal melanoma patients.
EGF IFN-c IL-1a IL-1b IL-2 IL-4 IL-6 IL-8 IL-10 MCP-1 TNF-a
VEGF 0.934 0.369 0.797 0.863 0.709 0.371 0.034 0.030 0.494 0.432 0.739
TNF-a 0.764 0.169 0.563 0.418 0.372 0.100 0.187 0.482 0.303 0.648
MCP-1 0.524 0.371 0.431 0.979 0.561 0.753 0.057 0.071 0.105
IL-10 0.095 0.926 0.063 0.337 0.129 0.619 0.496 0.820
IL-8 0.975 0.052 0.466 0.581 0.645 0.422 0.107
IL-6 0.223 0.494 0.335 0.207 0.864 0.313
IL-4 0.363 <0.001 0.019 0.186 0.091
IL-2 0.035 0.330 0.800 0.416
IL-1b 0.879 0.084 0.697
IL-1a 0.174 0.113
IFN-c 0.720
EGF = epidermal growth factor; IFN = interferon; IL = interleukin; MCP = monocyte chemoattractant protein; TNF = tumour necrosis fac-
tor; VEGF = vascular endothelial growth factor.
* Spearman’s correlation.
 Positive correlation with p-values <0.05.
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the cross-talk between uveal mela-
noma cells and TAMs (Cools-Lartigue
et al. 2004). High density of TAMs
was reported to correlate with
decreased survival (Makitie et al.
2001). A recent study showed that
brachytherapy increased the number
of macrophages within the sclera
under the tumour, which also corre-
lated with increasing numbers of
TAMs (Toivonen & Kivela 2010).
Tumour-associated macrophages
are recruited from circulating mono-
cytes into tissues in response to
chemoattractants such as MCP-1. An
elevated aqueous humour level of
MCP-1 was shown to be correlated
with TAM in uveal melanoma in a
recent study (Ly et al. 2010). In other
malignancies, such as breast cancer,
MCP-1 correlated with TAMs and
disease progression (Fujimoto et al.
2009). MCP-1 can also promote
angiogenesis by itself and inhibition of
MCP-1 resulted in reduced angiogene-
sis and growth of cutaneous mela-
noma in a mouse model (Koga et al.
2008). Further studies are necessary to
understand the role of MCP-1 in
uveal melanoma progression.
Originally described as a chemotac-
tic factor for leukocytes, IL-8 belongs
to the superfamily of CXC chemokines
and is highly angiogenic. It has
been associated with tumorigenesis
and even metastasis in numerous
tumours including cutaneous mela-
noma (Bar-Eli 1999). IL-8 can directly
promote angiogenesis (Li et al. 2003)
or can facilitate angiogenesis by stim-
ulating VEGF expression (Martin
et al. 2009). We found that IL-8 was
highly expressed in larger tumours
with greater height (p = 0.020), which
may suggest its role in tumorigenesis
of uveal melanoma.
Leukocytes from late-stage uveal
melanoma patients secrete increased
amounts of INF-c, so it was proposed
as a negative prognostic marker
(Likhvantseva et al. 1999). Many
tumours, including cutaneous mela-
noma, become resistant to INF-c, and
this may also be the case for uveal
melanoma (Hallermalm et al. 2008).
Many studies have dealt with
VEGF, a potent angiogenic factor, to
look for its implications in uveal mel-
anoma. Vascular endothelial growth
factor has been reported as highly
expressed in the aqueous humour
and ⁄or vitreous humour of uveal mel-
anoma patients (Missotten et al. 2006;
Ly et al. 2010). However, VEGF
mRNA and protein was not signiﬁ-
cantly expressed in uveal melanoma,
unlike retinoblastoma in one study
(Kvanta et al. 1996). There appears to
be no correlation between VEGF
expression and metastasis in uveal
melanoma (Sheidow et al. 2000; Ly
et al. 2010). Although aqueous VEGF
level was elevated in our cases, this
was not statistically signiﬁcant.
Increased VEGF level may be par-
tially attributed to the associated ser-
ous retinal detachment, as detached
retina can also be the source of VEGF
(Missotten et al. 2006). Aqueous
VEGF level correlated with the degree
of retinal detachment in this study. It
may be noteworthy that no tumour
involved ciliary body in our cohort;
melanomas involving ciliary body
appear to express higher level of
VEGF than tumours without ciliary
body involvement (Missotten et al.
2006), which may partially explain rel-
atively lower VEGF level in this
study. Whether VEGF expression is
implicated in uveal melanoma requires
further study.
We found that expressions of IL-6,
IL-8 and IL-1b were acutely elevated
in uveal melanoma after brachythera-
py. Radiation kills tumour cells basi-
cally in two ways: indirect and direct.
The indirect effect is believed to be a
more common mechanism and results
from the generation of free radicals in
the cells via ionization by photons.
Free radicals, in turn, damage DNA
or some other vital components of the
cell, causing cell death. The direct
Fig. 1. A graph showing a positive correlation between scleral contact dose of Ru-106 brachy-
therapy and increase in interleukin-6 concentration during therapy (R2 = 0.392; p = 0.003).
Fig. 2. A graph showing a positive correlation between scleral contact dose of Ru-106 brachy-
therapy and increase in interleukin-8 concentration during therapy (R2 = 0.203; p = 0.046).
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effect is a result of photons themselves
interacting directly with the cells caus-
ing cell death. If tumour cells die fol-
lowing irradiation, cytokines that are
presumably produced or induced by
tumour cells would also decrease after
therapy. However, this was not dem-
onstrated in this study; no cytokine
whose baseline level was elevated
decreased after treatment. Maybe it
was too early to reﬂect tumour con-
trol, as we obtained aqueous humour
after 117 hrs of irradiation on aver-
age. Acute increase in pro-inﬂamma-
tory cytokine expression, therefore,
appears to reﬂect radiation-induced
inﬂammation. Neurons are generally
resistant to radiation because they do
not divide on a regular basis. Rapidly
dividing cells, especially vascular
endothelial cells, are probably the
source of elevated IL-6 and IL-8 after
radiation (Meeren et al. 1997);
though, it may also be possible that
these cytokines were expressed from
tumour cells following radiation.
We found that an increase in IL-6
and IL-8 expressions was positively
correlated with an increase in scleral
contact dose and tumour height.
Unlike brachytherapy performed in
other medical ﬁelds, which irradiate
the tumour from all sides, episcleral
plaque therapy delivers radiation from
only one side. This leads to a steep
dose gradient in which the dose to the
sclera and the tumour are dependent
on the tumour height. Therefore,
tumour of greater height will receive
much higher sclera dose than tumours
of lesser height to achieve therapeutic
apex dose. Increased sclera dose and
tumour size have been associated with
increased risks for radiation retinopa-
thy, one of the most common vision-
threatening complication following
radiation (Puusaari et al. 2004). After
plaque brachytherapy, 42% and 8%
of patients developed non-proliferative
and proliferative retinopathy, respec-
tively, at 5 years follow-up in one
study (Shields et al. 2002). Clinical
features of radiation retinopathy are
similar to those of diabetic retinopa-
thy, and vitreous humour levels of IL-
6 and IL-8 have been shown to be
elevated in diabetic retinopathy, espe-
cially in proliferative types (Canataro-
glu et al. 2005). Other ocular
irradiation complications such as cata-
racts, neovascular glaucoma and uve-
itis are also related to inﬂammation
and angiogenesis, and cytokines such
as IL-6, IL-8 and IL-1b may have a
role in mediating these radiation-
related side effects. However, eleva-
tion of these cytokines in our study
reﬂects a short-term change after pla-
que radiotherapy and may not be sig-
niﬁcant for these side effects, as they
usually occur in a delayed manner.
Long-term follow-up would be neces-
sary to elucidate the implication of
these changes.
Limitations of this study include
small sample size and a combination
therapy including a single session of
TTT, which could have affected the
concentration of aqueous humour
cytokines independent of plaque ther-
apy. Tumours, transpupillary thermo-
therapy, however, was only applied to
the apex of the tumour as an adjunc-
tive treatment and thus may have not
contributed as signiﬁcantly to the
changes in cytokine proﬁles as the pla-
que radiotherapy.
In conclusion, this study demon-
strated that certain pro-inﬂammatory
and pro-angiogenic cytokines are
highly expressed in the aqueous
humour of uveal melanoma. IL-8, in
particular, was highly expressed in
tumours with greater heights and thus
possibly be associated with tumorigen-
esis in uveal melanoma as in other
malignancies. Combined brachythera-
py using Ru-106 and TTT resulted in
acute elevation of aqueous humour
levels of pro-inﬂammatory cytokines,
such as IL-6, IL-8 and IL-1b.
Increases in IL-6 and IL-8 levels posi-
tively correlated with scleral contact
radiation doses. Modulation of these
cytokines may be useful in managing
radiation-related side effects. This
study is limited by the small number
of patients, and its ﬁndings need con-
ﬁrmation in a larger study. Further
studies are warranted to investigate
the role of various cytokines, espe-
cially IL-6, IL-8, IFN-c and MCP-1,
in the progression of uveal melanoma.
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